Early-stage data shows that Viridian’s thyroid eye disease candidate induces clinically meaningful improvements in eye protrusion after six weeks of treatment.
Viridian Therapeutics (VRDN) Reports Positive Data from Ongoing Phase 1/2 Trial of VRDN-001 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg –
- Ongoing THRIVE Phase 3 trial in patients with active TED amended to reflect Viridian’s confidence in 5-dose regimen and key stakeholder feedback on evolving TED treatment paradigm -
- THRIVE-2 Phase 3 trial in patients with chronic TED expected to start in third quarter 2023 –
- 3 mg/kg data support low-volume subcutaneous (SC) dosing profile for Company’s SC candidates in TED -
- Viridian plans to select lead SC program candidate by year-end 2023; VRDN-001 SC IND amendment and VRDN-003 IND submitted to the FDA –
- Conference call and webcast to be held today, Monday, July 10th at 5:00 p.m. ET -
Highlights From Thyroid Eye Disease Forum: Drilling Down and Digging Deeper to Ensure Early Diagnosis and Treatment healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.